Literature DB >> 21061763

Changes in rosacea comorbidities and treatment utilization over time.

Brad A Yentzer1, Alan B Fleischer.   

Abstract

BACKGROUND: Rosacea is a chronic skin condition that requires lifelong treatment. Given the rise in antibiotic-resistant bacteria, many physicians are re-evaluating their use of antibiotics for long-term treatment of rosacea.
PURPOSE: To examine trends in the treatment of rosacea and the comorbidities associated with this skin condition.
METHODS: From 2002-2006, the National Ambulatory Medical Care Survey queried drug mentions at rosacea visits and coexisting diagnoses. Prescribing patterns of dermatologists were compared to other physicians' patterns.
RESULTS: Ten million physician visits had the diagnosis of rosacea; 74 percent were associated with co-morbidities. Metronidazole, tetracyclines, azelaic acid and sodium sulfacetamide were the top medications mentioned at rosacea visits. Prescriptions increased for azelaic acid and decreased for sodium sulfacetamide. Dermatologists decreased their prescribing of systemic medications.
CONCLUSION: Dermatologists are reducing their use of systemic antibiotics for rosacea and turning to therapies, such as azelaic acid, that do not have potential to induce bacterial resistance.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21061763

Source DB:  PubMed          Journal:  J Drugs Dermatol        ISSN: 1545-9616            Impact factor:   2.114


  2 in total

1.  Rate of Adverse Events and Healthcare Costs Associated with the Topical Treatment of Rosacea.

Authors:  Todd Williamson; Rajesh Kamalakar; Augustina Ogbonnaya; Erin A Zagadailov; Michael Eaddy; Charlie Kreilick
Journal:  Am Health Drug Benefits       Date:  2017-05

Review 2.  Managing Rosacea in the Clinic: From Pathophysiology to Treatment-A Review of the Literature.

Authors:  Sandra Marchese Johnson; Andrew Berg; Chelsea Barr
Journal:  J Clin Aesthet Dermatol       Date:  2020-04-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.